Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF BoardSTUDIO CITY, Calif., Nov. 26 ...

The following is a summary of “Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...

Previously, he served on the board for the Greater Pinebelt Community Foundation and participated in Sanofi’s Multiple Myeloma Journey Partners Program. Mr. Oliver aspires to become a disruptor ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...